Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
  • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/55—Phosphorus compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
  • A61K8/8164—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/02—Local antiseptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

• This invention relates to novel salts of arginine and compositions comprising them.
• Arginine and other basic amino acids have been proposed for use in oral care and are believed to have significant benefits in combating cavity formation and tooth sensitivity.
• the basic amino acid may raise the pH and facilitate dissociation of calcium ions that can react with fluoride ions to form an insoluble precipitate.
• lhe higher pH has the potential to cause irritation.
• a system utilizing arginine bicarbonate (which the art teaches is preferred) may release carbon dioxide, leading to bloating and bursting of the containers.
• the invention thus provides in one embodiment a salt of arginine and one or more of the following cations i. an acidic polymer, e.g., a polycarboxylatc polymer; ii. the conjugate acid of an anionic surfactant, e.g., lauroyl sulfuric acid; iii. a polyphosphoric or polyphosphonic acid, e.g.. hexamelaphosphoric acid; or iv. an acidic antimicrobial agent, e.g., gallic acid.
• an acidic polymer e.g., a polycarboxylatc polymer
• the conjugate acid of an anionic surfactant e.g., lauroyl sulfuric acid
• iii. a polyphosphoric or polyphosphonic acid e.g... hexamelaphosphoric acid
• an acidic antimicrobial agent e.g., gallic acid.
• the invention provides oral and personal care products comprising the salts of the invention, and methods of making and using the salts and products.
• the salt can be used in compositions to promote oral health and/or systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues.
• the invention provides a salt of arginine and an acidic polymer, e.g., a polymeric polycarboxylate, for example,
• Salt 1.0 wherein the polymeric polycarboxylate is a 1 :4 to 4: 1 copolymer of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer.
• salt 1.0.1 wherein the polycarboxylate comprises units formed of maleic anhydride and methyl vinyl ether, e.g., depicted at pH 7 as follows:
• the invention provides a salt of arginine and the conjugate acid of an anionic surfactant salt (Salt 2.0).
• Salt 2.0 an anionic surfactant salt
• salt 2.0 wherein the conjugate acid is of an anionic surfactant salt is selected from a. water-soluble salts of higher fatty acid monoglyccride inonosulfate (e.g.. salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids such as sodium N-methyl N-cocoyl taurate. sodium cocomo-glyceride sulfate). b. higher alkyl sulfates, e.g., sodium lauryl sulfate, c. higher alkyl-ether sulfates, e.g.. of formula
• Salt 2.0 or 2.0.1 which is a salt of arginine and lauroyl sulfuric acid.
• the invention provides arginine polyphosphate or polyphosphonate salts (Salt 3.0), for example:
• the invention provides salts of arginine and an antibacterial acid (Salt 4.0).
• Salt 4.0.1 the invention provides salts of arginine and a benzoic acid optionally substituted with carboxy and/or one or more, e.g., 1. 2, or 3 hydroxys, e.g., benzoic acid, phthalic acid, salicylic acid or trihydroxybenzoic acid, for example, gallic acid.
• composition 1.1 an oral care composition comprising any of Salts 1.0 - 1.0.4; 2.0 - 2.0.2, 3.0 - 3.0.5 or 4.0 - 4.0.1 , e.g.,
• Composition 1.1 further comprising an antibacterial agent.
• the antibacterial agent may be selected from halogenated diphenyl ether (e.g. triclosan), herbal extracts and essential oils (e.g., rosemary extract, tea extract, magnolia extract, thymol, menthol, eucalyptol, geraniol. carvacrol, citral, hinokitol. catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin. gallic acid, miswak extract, sea-buckthorn extract), bisguanide antiseptics (e.g.. chlorhexidine, alexidine or octenidine). quaternary ammonium compounds (e.g...).
• cetylpyridinium chloride CPC
• benzalkonium chloride tetradecylpyridinium chloride
• TPC tetradecylpyridinium chloride
• TDEPC N-tetradecyl-4-ethylpyridinium chloride
• phenolic antiseptics hexetidine. octenidine, sanguinarine. povidone iodine, delmopinol. salifluor.
• metal ions e.g., zinc salts, for example, zinc citrate, stannous salts, copper salts, iron salts), sanguinarine, propolis and oxygenating agents (e.g., hydrogen peroxide, buffered sodium peroxyborate or peroxycarbonate), phthalic acid and its salts, monoperthalic acid and its salts and esters, ascorbyl stearale, oleoyl saicosine, alkyl sulfate, dioctyl sulfosuccinate, salicylanilide, domiphen bromide, delmopinol, octapinol and other piperidino derivatives, irrigationn preparations, chlorite salts; and mixtures of any of the foregoing.
• oxygenating agents e.g., hydrogen peroxide, buffered sodium peroxyborate or peroxycarbonate
• phthalic acid and its salts e.g., monoperthalic acid and its salts and esters
• composition comprising triclosan and Zn 2+ ion source, e.g.. zinc citrate.
• compositions further comprising an anti-calculus agent.
• compositions further comprising an anti-calculus agent which is a polyphosphate, e.g.. pyrophosphate, tripolyphosphate, or hexametaphosphate. e.g., in sodium salt form.
• an anti-calculus agent which is a polyphosphate, e.g.. pyrophosphate, tripolyphosphate, or hexametaphosphate. e.g., in sodium salt form.
• compositions further comprising a fluoride ion source.
• Composition 1.1.6 wherein the fluoride ion source is a soluble fluoride salt selected from stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate. ammonium fluorosilicate. amine fluoride (e.g., N'-octadecyltrimethylendiamine-N.N,N'- tris(2-ethanol)-dihydro fluoride), ammonium fluoride, titanium fluoride, hexafluorosulfate, and combinations thereof.
• a soluble fluoride salt selected from stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate. ammonium fluorosilicate.
• amine fluoride e.g., N'-octadecyltrimethylendiamine-N.N,N'- tris(2-ethanol)-dihydro fluoride
• compositions further comprising a surfactant.
• compositions further comprising an agent that interferes with or prevents bacterial attachment, e.g., solbrol or chitosan.
• compositions in the form of a toothpaste optionally further comprising one or more of one or more of water, abrasives, surfactants, foaming agents, vitamins, polymers, enzymes, humectants, thickeners, antimicrobial agents, preservatives, flavorings, colorings and/or combinations thereof.
• the invention further comprises a method to improve oral health comprising applying an effective amount of any of Salts 1.0 - 1.0.4: 2.0 - 2.0.2. 3.0 - 3.0.5 or 4.0 - 4.0.1 , or any of Compositions 1.1 - 1.1.9 to the oral cavity of a subject in need thereof to i. reduce or inhibit formation of dental caries. ii. reduce, repair or inhibit early enamel lesions, iii. reduce or inhibit demineralization and promote remineralization of the teeth, iv. reduce hypersensitivity of the teeth. v. reduce or inhibit gingivitis, vi. promote healing of sores or cuts in the mouth, vii. reduce levels of acid producing bacteria, viii. to increase relative levels of arginolytic bacteria, ix.
• x. raise and/or maintain plaque pH at levels of at least pH about 5.5 following sugar challenge.
• xi. reduce plaque accumulation, xii. treat, relieve or reduce dry mouth, xiii. whiten teeth, xiv. enhance systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues, xv. reduce erosion of the teeth.
• xvi. immunize the teeth against cariogenic bacteria, and/or xvii. clean the teeth and oral cavity.
• the invention further provides the use of any of Salts 1.0 - 1.0.4; 2.0 - 2.0.2, 3.0 - 3.0.5 or 4.0 - 4.0.1 , or any of Compositions 1.1 - 1.1.9. for any of the above-listed indications.
• the basic amino acid is present in an amount of about 0.5 wt. % to about 20 wt. % of the total composition weight, about 1 wt. % to about 10 wt. % of the total composition weight, for example about 1.5 wt. %, 3.75 wt. %, 5 wt. %, or 7.5 wt. % of the total composition weight.
• the oral care compositions may further include one or more fluoride ion sources, e.g., soluble fluoride salts.
• fluoride ion sources e.g., soluble fluoride salts.
• fluoride ion-yielding materials can be employed as sources of soluble fluoride in the present compositions. Examples of suitable fluoride ion- yielding materials are found in U.S. Pat. No. 3,535.421 , to Briner et al.; U.S. Pat. No. 4.885,155, to Parran, Jr. et al. and U.S. Pat. No. 3.678,154, to Widder et al., incorporated herein by reference.
• Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate. ammonium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof.
• the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof.
• the oral care composition of the invention may also contain a source of fluoride ions or fluorine-providing ingredient in amounts sufficient to supply about 25 ppm to about 25,000 ppm of fluoride ions, generally at least about 500 ppm. e.g., about 500 to about 2000 ppm, e.g., about 1000 to about 1600 ppm, e.g., about 1450 ppm.
• the appropriate level of fluoride will depend on the particular application.
• a mouthwash for example, would typically have about 100 to about 250 ppm fluoride.
• a toothpaste for general consumer use would typically have about 1000 to about 1500 ppm, with pediatric toothpaste having somewhat less.
• a dentifrice or coating for professional application could have as much as about 5,000 or even about 25,000 ppm fluoride.
• Fluoride ion sources may be added to the compositions of the invention at a level of about 0.01 ⁇ vt. % to about 10 wt. % in one embodiment or about 0.03 ⁇ vt. % to about 5 ⁇ vt. %, and in another embodiment about 0.1 wt. % to about 1 wt. % by weight of the composition in another embodiment.
• Weights of fluoride salts to provide the appropriate level of fluoride ion will obviously vary based on the weight of the counter ion in the salt.
• the Compositions of the Invention may comprise a calcium phosphate abrasive, e.g., tricalcium phosphate (Ca 3 (PCu) 2 ). hydroxyapatite (Caio(P0 4 ) 6 (OH) 2 ), or dicalcium phosphate dihydrate (CaHPO 4 • 2H 2 O, also sometimes referred to herein as DiCaI) or calcium pyrophosphate.
• a calcium phosphate abrasive e.g., tricalcium phosphate (Ca 3 (PCu) 2 ).
• hydroxyapatite Caio(P0 4 ) 6 (OH) 2
• DiCaI dicalcium phosphate dihydrate
• calcium pyrophosphate calcium pyrophosphate
• compositions may include one or more additional abrasives, for example silica abrasives such as precipitated silicas having a mean particle size of up to about 20 microns, such as Zeodent 1 15 ® , marketed by J, M. Huber.
• additional abrasives for example silica abrasives such as precipitated silicas having a mean particle size of up to about 20 microns, such as Zeodent 1 15 ® , marketed by J, M. Huber.
• Other useful abrasives also include sodium metaphosphatc, potassium melaphosphate. aluminum silicate, calcined alumina, bentonite or other siliceous materials, or combinations thereof.
• the silica abrasive polishing materials useful herein, as well as the other abrasives generally have an average particle size of about 0.1 to about 30 microns, about 5 to about 15 microns.
• the silica abrasives can be from precipitated silica or silica gels, such as the silica xerogels described in U.S. Pat. No. 3,538,230. to Pader et al. and U.S. Pat. No. 3.862,307. to Digiulio, both incorporated herein by reference.
• Particular silica xerogels are marketed under the trade name Syloid* 1 by the W. R. Grace & Co.. Davison Chemical Di ⁇ ision.
• the precipitated silica materials include those marketed by the J. M. Huber Corp. under the trade name Zeodent 11' , including the silica carrying the designation Zeodent 1 15 and 1 19. These silica abrasives are described in U.S. Pat. No. 4.340,583. to Wason, incorporated herein by reference.
• abrasive materials useful in the practice of the oral care compositions in accordance with the invention include silica gels and precipitated amorphous silica having an oil absorption value of about less than 100 cc/100 g silica or about 45 cc/100 g to about 70 cc/100 g silica. Oil absorption values are measured using the ASTM Rub-Out Method D281.
• the silicas are colloidal particles having an average particle size of about 3 microns to about 12 microns, and about 5 to about 10 microns.
• the abrasive materials comprise a large fraction of very small particles, e.g., having a d50 less than about 5 microns, for example, small particle silica (SPS) having a d50 of 3-4 microns, for example Sorbosil AC43® (Ineos).
• SPS small particle silica
• Sorbosil AC43® Sorbosil AC43®
• Such small particles are particularly useful in formulations targeted at reducing hypersensitivity.
• the small particle component may be present in combination with a second larger particle abrasive.
• the formulation comprises about 3 to about 8% SPS and about 25 to about 45% of a conventional abrasive.
• Low oil absorption silica abrasives particularly useful in the practice of the invention are marketed under the trade designation Sylodent XWA 8 by Davison Chemical Division of W.R. Grace & Co.. Baltimore. Md. 21203. Sylodent 650 XWA 8 .
• a silica hydrogel composed of particles of colloidal silica having a water content of 29% by weight averaging about 7 to about 10 microns in diameter, and an oil absorption of less than about 70 cc/100 g of silica is an example of a low oil absorption silica abrasive useful in the practice of the present invention.
• the abrasive is present in the oral care composition of the present invention at a concentration of about 10 to 60% by weight, in other embodiment about 20 to 45% by weight, and in another embodiment about 30 to 50% by weight.
• the oral care compositions of the invention also may include an agent to increase the amount of foam that is produced when the oral cavity is brushed.
• agents that increase the amount of foam include, but are not limited to polyoxyethylene and certain polymers including, but not limited to, alginate polymers.
• the polyoxyethylene may increase the amount of foam and the thickness of the foam generated by the oral care carrier component of the present invention.
• Polyoxyethylene is also commonly known as polyethylene glycol ("PEG") or polyethylene oxide.
• PEG polyethylene glycol
• the polyoxyethylenes suitable for this invention will have a molecular weight of about 200,000 to about 7.000.000. In one embodiment the molecular weight will be about 600,000 to about 2.000,000 and in another embodiment about 800,000 to about 1 ,000,000.
• Polyox ® is the trade name for the high molecular weight polyoxyethylene produced by Union Carbide.
• the polyoxyethylene may be present in an amount of about 1 % Io about 90%, in one embodiment about 5% to about 50% and in another embodiment about 10% to about 20% by weight of the oral care carrier component of the oral care compositions of the present invention.
• the dosage of foaming agent in the oral care composition i.e.. a single dose
• the dosage of foaming agent in the oral care composition is about 0.01 to about 0.9 % by weight, about 0.05 to about 0.5% by weight, and in another embodiment about 0.1 to about 0.2 % by weight.
• Another agent optionally included in the oral care composition of the invention is a surfactant or a mixture of compatible surfactants.
• Suitable surfactants arc those which arc reasonably stable throughout a wide pH range, for example, anionic, cationic, nonionic or zwitterionic surfactants.
• Suitable surfactants are described more fully, for example, in U.S. Pat. No. 3.959,458. to Agricola et al.; U.S. Pat. No. 3,937,807. to Haefele: and U.S. Pat. No. 4.051.234. to Gieske et al.. which are incorporated herein by reference.
• the anionic surfactants useful herein include the water- soluble salts of alkyl sulfates having about 10 to about 18 carbon atoms in the alkyl radical and the water-soluble salts of sulfonated monoglycerides of fatty acids having about 10 to about 18 carbon atoms.
• Sodium lauryl sulfate, sodium lauroyl sarcosinate and sodium coconut monoglyceride sulfonates are examples of anionic surfactants of this type. Mixtures of anionic surfactants may also be utilized.
• cationic surfactants useful in the present invention can be broadly defined as derivatives of aliphatic quaternary ammonium compounds having one long alkyl chain containing about 8 to about 18 carbon atoms such as lauryl trimethylammonium chloride, cetyl pyridinium chloride, cetyl trimethylammonium bromide, di-isobutylphenoxyethyldimethylbenzylammonium chloride, coconut alkyltrimethylammonium nitrite, cetyl pyridinium fluoride, and mixtures thereof.
• Illustrative cationic surfactants are the quaternary ammonium fluorides described in U.S. Pat. No. 3,535,421 , to Briner et al.. herein incorporated by reference. Certain cationic surfactants can also act as germicides in the compositions.
• Illustrative nonionic surfactants that can be used in the compositions of the invention can be broadly defined as compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkylaromatic in nature.
• nonionic surfactants include, but are not limited to, the Pluronics, polyethylene oxide condensates of alkyl phenols, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene diamine, ethylene oxide condensates of aliphatic alcohols, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides and mixtures of such materials.
• zwitterionic synthetic surfactants useful in the present invention can be broadly described as derivatives of aliphatic quaternary ammonium, phosphomium, and sulfonium compounds, in which the aliphatic radicals can be straight chain or branched, and wherein one of the aliphatic substituents contains about 8 to about 18 carbon atoms and one contains an anionic water-solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate or phosphonate.
• Illustrative examples of the surfactants suited for inclusion into the composition include, but are not limited to. sodium alkyl sulfate, sodium lauroyl sarcosinate, cocoamidopropyl betaine and polysorbate 20, and combinations thereof.
• the Composition of the Invention comprises an anionic surfactant, e.g.. sodium lauryl sulfate.
• the surfactant or mixtures of compatible surfactants can be present in the compositions of the present invention in about 0.1% to about 5.0%, in another embodiment about 0.3% to about 3.0% and in another embodiment about 0.5% to about 2.0% by weight of the total composition.
• the oral care compositions of the invention may also include a flavoring agent.
• Flavoring agents which are used in the practice of the present invention include, but are not limited to. essential oils as well as various flavoring aldehydes, esters, alcohols, and similar materials.
• the essential oils include oils of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, lime, grapefruit, and orange. Also useful are such chemicals as menthol, carvone, and anethole. Certain embodiments employ the oils of peppermint and spearmint.
• the flavoring agent is incorporated in the oral composition at a concentration of about 0.1 to about 5% by weight and about 0.5 to about 1.5% by weight.
• the dosage of flavoring agent in the individual oral care composition dosage (i.e.. a single dose) is about 0.001 to 0.05% by weight and in another embodiment about 0.005 to 0.015 % by weight.
• the oral care compositions of the invention also may optionally include one or more chelating agents able to complex calcium found in the cell walls of the bacteria. Binding of this calcium weakens the bacterial cell wall and augments bacterial lysis.
• the pyrophosphate salts used in the present compositions can be any of the alkali metal pyrophosphate salts.
• salts include tetra alkali metal pyrophosphate, dialkali metal diacid pyrophosphate, trialkali metal monoacid pyrophosphate and mixtures thereof, wherein the alkali metals are sodium or potassium.
• the salts are useful in both their hydrated and unhydrated forms.
• An effective amount of pyrophosphate salt useful in the present composition is generally enough to provide at least 1.0 wt. % pyrophosphate ions, about 1.5 wt. % to about 6 vvl. %, about 3.5 ⁇ vt. % to about 6 wt. % of such ions.
• the oral care compositions of the invention also optionally include one or more polymers, such as polyethylene glycols, polyvinylmethyl ether maleic acid copolymers, polysaccharides (e.g., cellulose derivatives, for example carboxymethyl cellulose, or polysaccharide gums, for example xanthan gum or carrageenan gum).
• polysaccharides e.g., cellulose derivatives, for example carboxymethyl cellulose, or polysaccharide gums, for example xanthan gum or carrageenan gum.
• Acidic polymers for example polyacrylate gels, may be provided in the form of their free acids or partially or fully neutralized water soluble alkali metal (e.g., potassium and sodium) or ammonium salts.
• noncationic antibacterial agents or antibacterial agents are included in any of the dentifrice components, there is also preferably included from about 0.05 to about 5% of an agent which enhances the delivery and retention of the agents to, and retention thereof on oral surfaces.
• agents useful in the present invention are disclosed in U.S. Pat. Nos. 5, 188,821 and 5,192.531 ; and include synthetic anionic polymeric polycarboxylates. such as 1 :4 to 4:1 copolymers of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer, preferably methyl vinyl ether/maleic anhydride having a molecular weight (M.
• operative polymers include those such as the 1 : 1 copolymers of maleic anhydride with ethyl acrylate, hydroxyethyl methacrylate, N-vinyl-2-pyrollidonc, or ethylene, the latter being available for example as Monsanto EMA No. 1 103, M.W. 10,000 and EMA Grade 61. and 1 : 1 copolymers of acrylic acid with methyl or hydroxyethyl methacrylate, methyl or ethyl acrylate, isobutyl vinyl ether or N-vinyl-2-pyrrolidonc.
• Suitable generally are polymerized olefinically or ethylenically unsaturated carboxylic acids containing an activated carbon-to-carbon olefinic double bond and at least one carboxyl group, that is, an acid containing an olefinic double bond which readily functions in polymerization because of its presence in the monomer molecule either in the alpha-beta position with respect to a carboxyl group or as part of a terminal methylene grouping.
• Illustrative of such acids are acrylic, methacrylic, ethacrylic, alpha-chloroacrylic.
• a further class of polymeric agents includes a composition containing homopolymers of substituted acrylamides and/or homopolymers of unsaturated sulfonic acids and salts thereof, in particular where polymers are based on unsaturated sulfonic acids selected from acrylamidoalykane sulfonic acids such as 2-acrylamide 2 methylpropane sulfonic acid having a molecular weight of about 1.000 to about 2.000,000, described in U.S. Pat. No. 4.842,847, Jim. 27, 1989 to Zahid, incorporated herein by reference.
• polyamino acids particularly those containing proportions of anionic surface-active amino acids such as aspartic acid, glutamic acid and phosphoserine, as disclosed in U.S. Pat. No. 4,866.161 Sikes ct al., incorporated herein by reference.
• the thickening agents are carboxyvinyl polymers, carrageenan, hydroxyethyl cellulose and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose.
• Natural gums such as karaya, gum arabic. and gum tragacanth can also be incorporated.
• Colloidal magnesium aluminum silicate or finely divided silica can be used as component of the thickening composition to further improve the composition's texture.
• thickening agents in an amount of about 0.5% to about 5.0% by weight of the total composition are used.
• the oral care compositions of the invention may also optionally include one or more enzymes.
• Useful enzymes include any of the available proteases, glucanohydrolases, endoglycosidases, amylases, mutanases. lipases and mucinases or compatible mixtures thereof.
• the enzyme is a protease, dcxtranase, endoglycosidase and mutanase.
• the enzyme is papain, endoglycosidase or a mixture of dextranase and mutanase. Additional enzymes suitable for use in the present invention are disclosed in U.S. Pat. No.
• An enzyme of a mixture of several compatible enzymes in the current invention constitutes about 0.002% to about 2.0% in one embodiment or about 0.05% to about 1.5% in another embodiment or in yet another embodiment about 0.1 % to about 0.5%.
• Water may also be present in the oral compositions of the invention.
• Water employed in the preparation of commercial oral compositions should be deionized and free of organic impurities. Water commonly makes up the balance of the compositions and includes about 10% to about 90%, about 20% to about 60% or about 10% to about 30% by weight of the oral compositions. This amount of water includes the free water which is added plus that amount which is introduced with other materials such as with sorbitol or any components of the invention.
• humectant to prevent the composition from hardening upon exposure to air.
• Certain humectants can also impart desirable sweetness or flavor to dentifrice compositions.
• the humectant. on a pure humectant basis generally includes about 15% to about 70% in one embodiment or about 30% to about 65% in another embodiment by weight of the dentifrice composition.
• Suitable humectants include edible polyhydric alcohols such as glycerine, sorbitol, xylitol, propylene glycol as well as other polyols and mixtures of these humectants. Mixtures of glycerine and sorbitol may be used in certain embodiments as the humectant component of the toothpaste compositions herein.
• the embodiments of this invention can contain a variety of optional dentifrice ingredients some of which are described below.
• Optional ingredients include, for example, but are not limited to, adhesives, sudsing agents, flavoring agents, sweetening agents, additional antiplaque agents, abrasives, and coloring agents. These and other optional components are further described in U.S. Pat. No. 5.004.597, to Majeti; U.S. Pat. No. 3,959.458 Io Agricola et al. and U.S. Pat. No. 3,937,807. to Haefele, all being incorporated herein by reference.
• compositions of the present invention can be made using methods which arc common in the oral product area.
• the Salts are made by neutralizing arginine in a gel phase with the conjugate acid and mixing to form Premix 1. adjusting the pli to the desired level, and then combining with the other ingredients. Actives such as, for example, vitamins, CPC. fluoride, abrasives, and any other desired active ingredients are added to Premix 1 and mixed to form Premix 2. Where the final product is a toothpaste, a toothpaste base, for example, dicalcium phosphate or silica, is added to Premix 2 and mixed. The final slurry is formed into an oral care product.
• a toothpaste base for example, dicalcium phosphate or silica
• the present invention in its method aspect involves applying to the oral cavity a safe and effective amount of the compositions described herein.
• compositions and methods according to the invention are useful to a method to protect the teeth by facilitating repair and remineralization, in particular to reduce or inhibit formation of dental caries, reduce or inhibit demineralization and promote remineralization of the teeth, reduce hypersensitivity of the teeth, and reduce, repair or inhibit early enamel lesions, e.g., as detected by quantitative light-induced fluorescence (QLF) or electronic caries monitor (ECM).
• QLF quantitative light-induced fluorescence
• ECM electronic caries monitor
• Quantitative Light-induced Fluorescence is a visible light fluorescence that can detect early lesions and longitudinally monitor the progression or regression.
• the area of demineralization can be quantified and its progress monitored. Blue laser light is used to make the teeth auto fluoresce. Areas that have lost mineral have lower fluorescence and appear darker in comparison to a sound tooth surface.
• Software is used to quantify the fluorescence from a white spot or the area/volume associated with the lesion. Generally, subjects with existing white spot lesions are recruited as panelists. The measurements are performed in vivo with real teeth.
• the lesion area/volume is measured at the beginning of the clinical.
• the reduction (improvement) in lesion area/volume is measured at the end of 6 months of product use. The data is often reported as a percent improvement versus baseline.
• Electrical Caries Monitoring is a technique used to measure mineral content of the tooth based on electrical resistance. Electrical conductance measurement exploits the fact that the fluid-filled tubules exposed upon demineralization and erosion of the enamel conduct electricity. As a tooth loses mineral, it becomes less resistive to electrical current due to increased porosity. An increase in the conductance of the patient's teeth therefore may indicate demineralization.
• studies are conducted of root surfaces with an existing lesion. The measurements are performed in vivo with real teeth. Changes in electrical resistance before and after 6 month treatments are made.
• a classical caries score for root surfaces is made using a tactile probe. The hardness is classified on a three point scale: hard, leathery, or soft. In this type of study, typically the results are reported as electrical resistance (higher number is better) for the ECM measurements and an improvement in hardness of the lesion based on the tactile probe score.
• compositions of the Invention are thus useful in a method to reduce early lesions of the enamel (as measured by QLF or ECM) relative to a composition lacking effective amounts of fluorine and/or arginine.
• compositions of the invention are additionally useful in methods to reduce harmful bacteria in the oral cavity, for example methods to reduce or inhibit gingivitis, reduce levels of acid producing bacteria, to increase relative levels of arginolytic bacteria, inhibit microbial biofilm formation in the oral cavity, raise and/or maintain plaque pH at levels of at least pH about 5.5 following sugar challenge, reduce plaque accumulation, and/or clean the teeth and oral cavity.
• compositions of the Invention are useful to promote healing of sores or cuts in the mouth.
• compositions and methods according to the invention can be incorporated into oral compositions for the care of the mouth and teeth such as toothpastes, transparent pastes, gels, mouth rinses, sprays and chewing gum.
• Enhancing oral health also provides benefits in systemic health, as the oral tissues can be gateways for systemic infections.
• Good oral health is associated with systemic health, including cardiovascular health.
• the compositions and methods of the invention provide particular benefits because basic amino acids, especially arginine, are sources of nitrogen which supply NO synthesis pathways and thus enhance microcirculation in the oral tissues. Providing a less acidic oral environment is also helpful in reducing gastric distress and creates an environment less favorable to Heliobacter, which is associated with gastric ulcers.
• Arginine in particular is required for high expression of specific immune cell receptors, for example T-cell receptors, so that arginine can enhance an effective immune response.
• the compositions and methods of the invention are thus useful to enhance systemic health, including cardiovascular health.
• ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range.
• all references cited herein are hereby incorporated by reference in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls. It is understood that when formulations are described, they may be described in te ⁇ ns of their ingredients, as is common in the art, notwithstanding that these ingredients may react with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Communicable Diseases (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Oncology (AREA)
• Cosmetics (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (11)

Applications Claiming Priority (8)

Publications (1)

Family

ID=40020250

Family Applications (1)

Country Status (19)

Cited By (6)

Families Citing this family (18)

Citations (20)

Family Cites Families (48)

• 2008
  • 2008-03-28 CN CN201910652331.6A patent/CN110302085A/zh active Pending
  • 2008-03-28 SG SG2013010020A patent/SG188132A1/en unknown
  • 2008-03-28 MY MYPI2010002033A patent/MY155564A/en unknown
  • 2008-03-28 US US12/058,387 patent/US20090202456A1/en not_active Abandoned
  • 2008-03-28 EP EP08744602.7A patent/EP2249785B2/en active Active
  • 2008-03-28 CL CL2008000897A patent/CL2008000897A1/es unknown
  • 2008-03-28 PE PE2008000563A patent/PE20091668A1/es not_active Application Discontinuation
  • 2008-03-28 CN CN2008801268941A patent/CN102036649A/zh active Pending
  • 2008-03-28 WO PCT/US2008/058658 patent/WO2009099451A1/en not_active Ceased
  • 2008-03-28 RU RU2010137265/15A patent/RU2010137265A/ru unknown
  • 2008-03-28 EP EP16172302.8A patent/EP3100716B1/en not_active Not-in-force
  • 2008-03-28 MX MX2012012787A patent/MX337177B/es unknown
  • 2008-03-28 AU AU2008349846A patent/AU2008349846B2/en active Active
  • 2008-03-28 MX MX2010005191A patent/MX2010005191A/es active IP Right Grant
  • 2008-03-28 JP JP2010545847A patent/JP2011511065A/ja active Pending
  • 2008-03-28 BR BRPI0821858-7A2A patent/BRPI0821858A2/pt not_active IP Right Cessation
  • 2008-03-28 MX MX2016002004A patent/MX367367B/es unknown
  • 2008-03-28 CA CA2706351A patent/CA2706351C/en not_active Expired - Fee Related
  • 2008-03-29 SA SA8290178A patent/SA08290178B1/ar unknown
  • 2008-03-31 AR ARP080101324A patent/AR069724A1/es not_active Application Discontinuation
  • 2008-04-07 TW TW103118200A patent/TW201509412A/zh unknown
  • 2008-04-07 TW TW097112586A patent/TW200934480A/zh unknown
• 2010
  • 2010-05-04 MY MYPI2014002231A patent/MY166789A/en unknown
  • 2010-05-24 ZA ZA2010/03688A patent/ZA201003688B/en unknown
  • 2010-09-02 CO CO10108686A patent/CO6300927A2/es active IP Right Grant
• 2014
  • 2014-10-27 JP JP2014218235A patent/JP2015042660A/ja not_active Withdrawn

Patent Citations (20)

Non-Patent Citations (9)

Also Published As

Similar Documents

Legal Events